[ad_1]
Of: TT
Published:
Photo: Kallestad, Gorm
The EU has signed an agreement to purchase 300 million doses of an upcoming covid-19 vaccine from Sanofi and Glaxo Smith Kline.
The EU has signed an agreement with pharmaceutical companies Sanofi and Glaxo Smith Kline to purchase 300 million doses of an upcoming COVID-19 vaccine, according to a press release from the European Commission. It is an extension of a collaboration that began in July.
Production is expected to take place at companies’ facilities in Belgium, Germany and France, and the EU will help with financing and other support to increase production capacity. The agreement also gives EU member states the right to donate doses of vaccines to low- and middle-income countries.
The vaccine is of a more classical type than the genetic vaccines produced by, for example, the Swedish-British Astra Zeneca and American Moderna. Sanofi produces antigen synthetically, which is then injected with an immunostimulatory adjuvant produced by Glaxo Smith Kline.
Phase 2 clinical trials began in early September and phase 3 studies are planned for the end of 2020.
Published:
